Biogen and UCB present positive Phase 3 PHOENYCS GO data for lupus candidate dapirolizumab pegol
Biogen (NASDAQ:BIIB) and UCB have announced the release of positive results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational treatment for systemic lupus erythematosus (SLE).


_1414180_640x360_2502471235783-640x360.webp&w=3840&q=75)
_1414160_640x360_2502472259524-640x360.webp&w=3840&q=75)
_1414147_640x360_2502467139706-640x360.webp&w=3840&q=75)
_1414142_640x360_2502464579856-640x360.webp&w=3840&q=75)
_1414126_640x360_2502466627773-640x360.webp&w=3840&q=75)
_1414122_640x360_2502457923725-640x360.webp&w=3840&q=75)
_1414124_640x360_2502460483999-640x360.webp&w=3840&q=75)
_1414118_640x360_2502466627507-640x360.webp&w=3840&q=75)
_1414078_640x360_2502450755908-640x360.webp&w=3840&q=75)
_1414074_640x360_2502455363830-640x360.webp&w=3840&q=75)